Sheldon Koenig - Esperion Therapeutics CEO President
| ESPR Stock | USD 2.54 0.03 1.17% |
CEO
Sheldon Koenig is CEO President of Esperion Therapeutics
| Age | 58 |
| Address | 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108 |
| Phone | 734 887 3903 |
| Web | https://www.esperion.com |
Sheldon Koenig Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sheldon Koenig against Esperion Therapeutics stock is an integral part of due diligence when investing in Esperion Therapeutics. Sheldon Koenig insider activity provides valuable insight into whether Esperion Therapeutics is net buyers or sellers over its current business cycle. Note, Esperion Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Esperion Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sheldon Koenig over six months ago Acquisition by Sheldon Koenig of 8606 shares of Esperion Therapeutics at 5.8041 subject to Rule 16b-3 | ||
Sheldon Koenig over six months ago Acquisition by Sheldon Koenig of 642000 shares of Esperion Therapeutics at 2.05 subject to Rule 16b-3 |
Esperion Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.0384 % which means that it generated a profit of $0.0384 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6079) %, meaning that it created substantial loss on money invested by shareholders. Esperion Therapeutics' management efficiency ratios could be used to measure how well Esperion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/28/2024, Return On Equity is likely to grow to 0.48, while Return On Tangible Assets are likely to drop (1.07). As of 11/28/2024, Debt To Assets is likely to grow to 2.74, while Total Assets are likely to drop slightly above 181.9 M.Similar Executives
| Found 9 records | CEO Age | ||
| James Hall | Lifecore Biomedical | 61 | |
| Vikram Karnani | Collegium Pharmaceutical | 49 | |
| Diem MBA | SIGA Technologies | 52 | |
| Kevin Gorman | Neurocrine Biosciences | 66 | |
| Jeffrey Simmons | Elanco Animal Health | 57 | |
| Frank Lee | Pacira BioSciences, | 56 | |
| Nikhil Lalwani | ANI Pharmaceuticals | 46 | |
| Paul Josephs | Lifecore Biomedical | 59 | |
| Mark Strobeck | Rockwell Medical | 53 | |
Management Performance
| Return On Equity | -2.61 | ||||
| Return On Asset | 0.0384 |
Esperion Therapeutics Leadership Team
Elected by the shareholders, the Esperion Therapeutics' board of directors comprises two types of representatives: Esperion Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Esperion. The board's role is to monitor Esperion Therapeutics' management team and ensure that shareholders' interests are well served. Esperion Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Esperion Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Benjamin JD, General Secretary | ||
| Benjamin MBA, Chief Officer | ||
| Glenn Brame, Chief Officer | ||
| Tiffany MBA, Associate Communications | ||
| Sheldon Koenig, CEO President | ||
| Ben MBA, Chief Officer | ||
| Betty Swartz, Chief Officer | ||
| Eric RPh, Chief Officer | ||
| Benjamin Looker, General Counsel | ||
| MD FACC, Chief Officer | ||
| Kenneth Fiorelli, Chief Officer |
Esperion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Esperion Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.61 | ||||
| Return On Asset | 0.0384 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 630.63 M | ||||
| Shares Outstanding | 197.04 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 66.33 % | ||||
| Number Of Shares Shorted | 31.25 M | ||||
| Price To Earning | (8.19) X |
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Esperion Stock
| 0.9 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Esperion Stock
| 0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.82 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.77 | PEPG | PepGen | PairCorr |
| 0.72 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.